<DOC>
	<DOCNO>NCT01901718</DOCNO>
	<brief_summary>Chronic pain patient experience breakthrough pain background control persistent pain opioids follow 3 month order ass safety titration trend clinical practice set novel fentanyl sublingual spray ( Subsys™ ) treatment breakthrough pain .</brief_summary>
	<brief_title>An Observational , Non-Interventional Trial Assess Patient Satisfaction Safety Subsys™ Spray .</brief_title>
	<detailed_description>Approximately 100 subject across 10 center throughout United States enrol study . Subjects currently take Actiq® breakthrough pain discontinue due lack efficacy , poor tolerability , patient prescriber dissatisfaction meet study inclusion criterion none exclusion criterion candidate receive sublingual fentanyl spray ( Subsys™ ) . The total duration study subject 4 month .</detailed_description>
	<mesh_term>Breakthrough Pain</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<criteria>Patients ≥ 18 year age . Subjects experience 14 episode break pain per day spite optimize background analgesia take least 60 mg/day morphine ( equivalent analgesic ) least 7 day . Who currently use Actiq® breakthrough pain discontinue due lack efficacy , side effect , patient dissatisfaction prescriber dissatisfaction treatment . Are able follow complete necessary study procedure . Are willing able give write informed consent participate study . Enrolled class wide REMS verify study personnel . Subjects opioid tolerant . Using rapid onset opioid Actiq® manage breakthrough pain . Have physical abnormality floor mouth could affect absorption determine investigator . Are subject uncontrolled rapidly escalate pain . Are subject history alcohol substance abuse within last 3 year . Have clinically significant medical history ( past present ) disease would compromise study wellbeing subject . Are subject participate another clinical trial analgesic within last month . Are female subject positive pregnancy test currently lactate . Are subject take medication know inhibitor CYP3A4 isozyme , ketoconazole . Are subject take monoamine inhibitor within 14 day dose study medication . Opioid use chronic migraine acute pain . Are subject unsuitable inclusion reason , opinion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Breakthrough Pain</keyword>
	<keyword>Subsys</keyword>
	<keyword>Fentanyl</keyword>
	<keyword>Opioid</keyword>
	<keyword>Persistent Pain</keyword>
</DOC>